Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2016

View Archived Issues

Selecta Biosciences announces new gene therapy programs

Novartis reviews highlights of second quarter 2016

Ruxolitinib receives orphan drug designation in U.S. for the treatment of ALL

Merck & Co. announces BTK inhibitors

Angion Biomedica presents aldosterone synthase inhibitors

FORMA Therapeutics patents ubiquitin hydrolase inhibitors

The Vanderbilt University reports mGlu2 receptor modulators

Shire launches pediatric indication for HyQvia in Europe

RBPJ inhibition as promising new therapeutic strategy for ischemic injury

EMA proposes changes to guidance on first-in-human trials

BiopharmX reports PK data for BPX-01

Helix BioPharma subsidiary finalizes Polish grant funding to support development of V-DOS47

RepliCel Life Sciences product cleared for clinical research in Japan

Newron Pharmaceuticals begins sarizotan study in Rett syndrome

Puma submits NDA for neratinib as extended adjuvant in HER2-positive early stage breast cancer

ABX-464 well tolerated in first study in HIV-infected patients, another under way

FDA issues complete response letter for latanoprostene bunod NDA

FDA requests new data and analyses to support bezlotoxumab BLA

SPHERE Registry to validate biomarkers in urine that predict genetic mutations

Cytox launches genetic biomarker test for assessing Alzheimer's disease risk

Cancer-prone BMF syndrome may be caused by mutations in DNAJC21

Amgen and UCB submit romosozumab BLA for osteoporosis in postmenopausal women

Novel Chlamydia vaccine using C. trachomatis T3SS proteins shows promise

Resverlogix begins dosing in phase I study of apabetalone in severe renal impairment

FDA gives fast track status to axalimogene filolisbac

Enhanced neural activity and mTOR signaling promotes regeneration of adult retinal axons

Novan begins dosing in phase II SB-208 study

FDA grants breakthrough therapy designation to Spark Therapeutics' SPK-9001

Amgen and Allergan report phase III results for ABP-980

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...